1. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer.
- Author
-
Tamura K, Yu J, Hata T, Suenaga M, Shindo K, Abe T, MacGregor-Das A, Borges M, Wolfgang CL, Weiss MJ, He J, Canto MI, Petersen GM, Gallinger S, Syngal S, Brand RE, Rustgi A, Olson SH, Stoffel E, Cote ML, Zogopoulos G, Potash JB, Goes FS, McCombie RW, Zandi PP, Pirooznia M, Kramer M, Parla J, Eshleman JR, Roberts NJ, Hruban RH, Klein AP, and Goggins M
- Subjects
- Aged, Aged, 80 and over, Cell Line, Tumor, Female, Humans, Male, Middle Aged, Carboxypeptidase B genetics, Carboxypeptidase B metabolism, Carboxypeptidases A genetics, Carboxypeptidases A metabolism, Endoplasmic Reticulum Stress genetics, Genetic Predisposition to Disease, Mutation, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Pancreatic Neoplasms enzymology, Pancreatic Neoplasms genetics, Pancreatic Neoplasms pathology
- Abstract
To evaluate whether germline variants in genes encoding pancreatic secretory enzymes contribute to pancreatic cancer susceptibility, we sequenced the coding regions of CPB1 and other genes encoding pancreatic secretory enzymes and known pancreatitis susceptibility genes ( PRSS1 , CPA1 , CTRC , and SPINK1 ) in a hospital series of pancreatic cancer cases and controls. Variants in CPB1 , CPA1 (encoding carboxypeptidase B1 and A1), and CTRC were evaluated in a second set of cases with familial pancreatic cancer and controls. More deleterious CPB1 variants, defined as having impaired protein secretion and induction of endoplasmic reticulum (ER) stress in transfected HEK 293T cells, were found in the hospital series of pancreatic cancer cases (5/986, 0.5%) than in controls (0/1,045, P = 0.027). Among familial pancreatic cancer cases, ER stress-inducing CPB1 variants were found in 4 of 593 (0.67%) vs. 0 of 967 additional controls ( P = 0.020), with a combined prevalence in pancreatic cancer cases of 9/1,579 vs. 0/2,012 controls ( P < 0.01). More ER stress-inducing CPA1 variants were also found in the combined set of hospital and familial cases with pancreatic cancer than in controls [7/1,546 vs. 1/2,012; P = 0.025; odds ratio, 9.36 (95% CI, 1.15-76.02)]. Overall, 16 (1%) of 1,579 pancreatic cancer cases had an ER stress-inducing CPA1 or CPB1 variant, compared with 1 of 2,068 controls ( P < 0.00001). No other candidate genes had statistically significant differences in variant prevalence between cases and controls. Our study indicates ER stress-inducing variants in CPB1 and CPA1 are associated with pancreatic cancer susceptibility and implicate ER stress in pancreatic acinar cells in pancreatic cancer development., Competing Interests: Conflict of interest statement: M.G., A.P.K., and R.H.H. have received royalties for the licensing of PALB2 as a pancreatic cancer susceptibility gene. S.S. is a consultant to Myriad Genetics, Inc. R.W.M. has participated in Illumina-sponsored meetings over the past 4 y and received travel reimbursement and an honorarium for presenting at these events. Illumina had no role in decisions relating to the study/work to be published, data collection and analysis of data, and the decision to publish. R.W.M. has participated in Pacific Biosciences-sponsored meetings over the past 3 y and received travel reimbursement for presenting at these events. R.W.M. is a founder and shared holder of Orion Genomics, which focuses on plant genomics and cancer genetics. R.W.M. is a scientific advisory board member for RainDance Technologies, Inc. None of the other authors has any conflicts of interest to declare.
- Published
- 2018
- Full Text
- View/download PDF